Manuel Hidalgo

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4198699/manuel-hidalgo-publications-by-year.pdf
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

234 papers	33,242 citations	77 h-index	181 g-index
247 ext. papers	37,395 ext. citations	9.5 avg, IF	7.19 L-index

#	Paper	IF	Citations
234	Saliva-Based, COVID-19 RT-PCR Pooled Screening Strategy to Keep Schools Open.. *Disaster Medicine and Public Health Preparedness*, **2022**, 1-6	2.8	0
233	Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441).. *Journal of Clinical Oncology*, **2022**, 40, 518-518	2.2	5
232	Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer. *Clinical Cancer Research*, **2021**,	12.9	9
231	Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids **2021**, 9,		4
230	VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. **2021**, 9,		5
229	Reply to K. de Joode et al. *Journal of Clinical Oncology*, **2021**, 39, 1093-1094	2.2	
228	Differentiated activity profile for the PD-1 inhibitor balstilimab.. *Journal of Clinical Oncology*, **2021**, 39, 5529-5529	2.2	1
227	Elevated levels of mitochondrial CoQ induce ROS-mediated apoptosis in pancreatic cancer. *Scientific Reports*, **2021**, 11, 5749	4.9	4
226	Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial. *Clinical Cancer Research*, **2021**, 27, 5020-5027	12.9	8
225	A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. *Clinical Cancer Research*, **2021**, 27, 5472-5481	12.9	0
224	Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. *Cell*, **2021**, 184, 4753-4771.e27	56.2	18
223	Clinical Screening for COVID-19 in Asymptomatic Patients With Cancer. *JAMA Network Open*, **2020**, 3, e2023121	10.4	12
222	CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. *Cancer Cell*, **2020**, 37, 340-353.e6	24.3	55
221	PDX-derived organoids model in vivo drug response and secrete biomarkers. *JCI Insight*, **2020**, 5,	9.9	25
220	COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study. *Journal of Clinical Oncology*, **2020**, 38, 3914-3924	2.2	67
219	Phase II trial of BPM31510-IV plus gemcitabine in advanced pancreatic ductal adenocarcinomas (PDAC).. *Journal of Clinical Oncology*, **2020**, 38, 723-723	2.2	3
218	TRYbeCA-1: A randomized, phase III study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).. *Journal of Clinical Oncology*, **2020**, 38, TPS4666-TPS4666	2.2	

217	BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. *Nature Medicine*, **2020**, 26, 878-885	50.5	126
216	From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. *Nature Reviews Clinical Oncology*, **2020**, 17, 108-123	19.4	122
215	Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. *Ca-A Cancer Journal for Clinicians*, **2020**, 70, 349-354	220.7	13
214	Lewis Antigen Phenotype and Survival of Patients With Pancreatic Cancer. *Pancreas*, **2020**, 49, 1348-1354	2.6	1
213	Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF. *Cancer Cell*, **2019**, 35, 573-587.e6	24.3	37
212	Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2. *Journal of Clinical Oncology*, **2019**, 37, 230-238	2.2	47
211	Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. *JCI Insight*, **2019**, 4,	9.9	59
210	Personalized RNA Medicine for Pancreatic Cancer. *Clinical Cancer Research*, **2018**, 24, 1734-1747	12.9	39
209	Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies. *Clinical Cancer Research*, **2018**, 24, 3550-3559	12.9	26
208	A Tricin Derivative from Desv. Inhibits Colorectal Carcinoma Growth and Liver Metastasis through the Induction of a Specific Immune Response. *Molecular Cancer Therapeutics*, **2018**, 17, 966-976	6.1	14
207	From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. *Journal of Cancer*, **2018**, 9, 1978-1988	4.5	14
206	More than a Gel & Hyaluronic Acid, a Central Component in the Microenvironment of Pancreatic Cancer. *European Oncology and Haematology*, **2018**, 14, 40	0.1	7
205	MT1-MMP as a PET Imaging Biomarker for Pancreas Cancer Management. *Contrast Media and Molecular Imaging*, **2018**, 2018, 8382148	3.2	5
204	Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. *International Journal of Cancer*, **2018**, 143, 2053-2064	7.5	44
203	Interrogating open issues in cancer precision medicine with patient-derived xenografts. *Nature Reviews Cancer*, **2017**, 17, 254-268	31.3	369
202	Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. *Journal of Clinical Oncology*, **2017**, 35, 157-165	2.2	268
201	Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin. *Clinical Cancer Research*, **2017**, 23, 5639-5647	12.9	50
200	GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer. *Epigenetics*, **2017**, 12, 540-550	3.7	31

199	Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective. *Public Health Genomics*, **2017**, 20, 81-91	1.9	6
198	A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. *Journal of Gastrointestinal Oncology*, **2017**, 8, 925-935	2.8	
197	Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2016**, 39, 236-42	2.7	5
196	Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. *Nature Medicine*, **2016**, 22, 270-7	50.5	115
195	SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. *Molecular Cancer Therapeutics*, **2016**, 15, 680-8	6.1	35
194	Rational Combinations of mTOR Inhibitors as Anticancer Strategies **2016**, 191-215		
193	Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. *British Journal of Cancer*, **2016**, 115, 442-53	8.7	29
192	Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms. *Clinical Cancer Research*, **2015**, 21, 2325-37	12.9	121
191	SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial. *Clinical Cancer Research*, **2015**, 21, 4811-8	12.9	101
190	Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice. *Cancer Research*, **2015**, 75, 3466-78	10.1	98
189	Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function. *Cancer Research*, **2015**, 75, 3355-64	10.1	106
188	A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. *Investigational New Drugs*, **2015**, 33, 710-9	4.3	17
187	Examining the utility of patient-derived xenograft mouse models. *Nature Reviews Cancer*, **2015**, 15, 311-6	31.3	246
186	Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. *Gut*, **2015**, 64, 1921-35	19.2	88
185	Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. *Nature Reviews Clinical Oncology*, **2015**, 12, 319-34	19.4	404
184	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. *New England Journal of Medicine*, **2015**, 373, 726-36	59.2	1172
183	Addressing the challenges of pancreatic cancer: future directions for improving outcomes. *Pancreatology*, **2015**, 15, 8-18	3.8	277
182	Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors. *Clinical Cancer Research*, **2015**, 21, 1002-9	12.9	30

181	Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. *Clinical Cancer Research* , **2015**, 21, 2462-70	12.9	42
180	The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. *Gut*, **2015**, 64, 1936-48	19.2	100
179	Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.. *Journal of Clinical Oncology*, **2015**, 33, 344-344	2.2	13
178	Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models Reveals Possible Driver Mutations Underlying Tumor Progression. *PLoS ONE*, **2015**, 10, e0142631	3.7	23
177	Phase I study of carboplatin in combination with PM00104 (Zalypsis) in patients with advanced solid tumors. *Investigational New Drugs*, **2014**, 32, 644-52	4.3	1
176	Colorectal cancer classification based on gene expression is not associated with FOLFIRI response. *Nature Medicine*, **2014**, 20, 1230-1	50.5	8
175	Patient-derived xenograft models: an emerging platform for translational cancer research. *Cancer Discovery*, **2014**, 4, 998-1013	24.4	1018
174	Intracellular autofluorescence: a biomarker for epithelial cancer stem cells. *Nature Methods*, **2014**, 11, 1161-9	21.6	131
173	Transcriptional dissection of pancreatic tumors engrafted in mice. *Genome Medicine*, **2014**, 6, 27	14.4	30
172	Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment. *Clinical Cancer Research*, **2014**, 20, 2476-84	12.9	118
171	Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling. *Molecular Cancer Therapeutics*, **2014**, 13, 1758-71	6.1	106
170	Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ. *Breast Cancer Research*, **2014**, 16, R76	8.3	10
169	Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer. *Clinical Cancer Research*, **2014**, 20, 5281-9	12.9	42
168	Metabolomic evaluation of Mitomycin C and rapamycin in a personalized treatment of pancreatic cancer. *Pharmacology Research and Perspectives*, **2014**, 2, e00067	3.1	14
167	A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2014**, 37, 117-21	2.7	22
166	Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. *PLoS ONE*, **2014**, 9, e107200	3.7	49
165	Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. *Journal of Clinical Oncology*, **2013**, 31, 4445-52	2.2	136
164	Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *New England Journal of Medicine*, **2013**, 369, 1691-703	59.2	3788

163	The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre. *Histopathology*, **2013**, 62, 609-16	7.3	13
162	Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. *International Journal of Radiation Oncology Biology Physics*, **2013**, 86, 678-85	4	30
161	Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma. *International Journal of Radiation Oncology Biology Physics*, **2013**, 87, 458-9	4	17
160	Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. *Cancer Letters*, **2013**, 335, 41-51	9.9	113
159	Primary human non-small cell lung and pancreatic tumorgraft models--utility and applications in drug discovery and tumor biology. *Current Protocols in Pharmacology*, **2013**, Chapter 14, Unit 14.26	4.1	15
158	Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. *Investigational New Drugs*, **2013**, 31, 345-54	4.3	16
157	The winning formulation: the development of paclitaxel in pancreatic cancer. *Clinical Cancer Research*, **2013**, 19, 5572-9	12.9	46
156	Personalized chemotherapy profiling using cancer cell lines from selectable mice. *Clinical Cancer Research*, **2013**, 19, 1139-46	12.9	21
155	Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. *PLoS ONE*, **2013**, 8, e76518	3.7	121
154	Tyrosine phosphorylation modulates the vascular responses of mesenteric arteries from human colorectal tumors. *BioMed Research International*, **2013**, 2013, 545983	3	2
153	The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors. *PLoS ONE*, **2013**, 8, e68966	3.7	23
152	Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. *PLoS ONE*, **2013**, 8, e66371	3.7	31
151	The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. *Molecular Cancer Therapeutics*, **2012**, 11, 1999-2009	6.1	68
150	Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. *Investigational New Drugs*, **2012**, 30, 2334-43	4.3	28
149	Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. *Investigational New Drugs*, **2012**, 30, 2391-9	4.3	85
148	Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. *Cancer Medicine*, **2012**, 1, 207-17	4.8	12
147	A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry. *PLoS ONE*, **2012**, 7, e43842	3.7	72
146	Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. *Clinical Cancer Research*, **2012**, 18, 4249-56	12.9	65

145	Stromal cell-derived factor 1 mediates resistance to mTOR-directed therapy in pancreatic cancer. *Neoplasia*, **2012**, 14, 690-701	6.4	40
144	An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity. *Proteomics*, **2012**, 12, 1319-27	4.8	22
143	HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. *Journal of Clinical Pathology*, **2012**, 65, 751-7	3.9	63
142	Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. *Journal of Clinical Oncology*, **2012**, 30, e45-8	2.2	72
141	From node to pathway blockade: lessons learned from targeting mammalian target of rapamycin. *Journal of Clinical Oncology*, **2012**, 30, 85-7	2.2	5
140	Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. *Clinical Cancer Research*, **2012**, 18, 1051-62	12.9	36
139	First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. *Oncologist*, **2012**, 17, 339-45	5.7	60
138	Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, E252-9	11.5	161
137	Getting personalized cancer genome analysis into the clinic: the challenges in bioinformatics. *Genome Medicine*, **2012**, 4, 61	14.4	22
136	Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. *Oncotarget*, **2012**, 3, 1416-27	3.3	40
135	Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. *Nature Structural and Molecular Biology*, **2011**, 18, 1331-1335	17.6	281
134	The inverted pyramid of biomarker-driven trials. *Nature Reviews Clinical Oncology*, **2011**, 8, 562-6	19.4	14
133	Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. *Cell Stem Cell*, **2011**, 9, 433-46	18	314
132	Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. *Histopathology*, **2011**, 59, 8-17	7.3	37
131	Early-onset colorectal cancer is an easy and effective tool to identify retrospectively Lynch syndrome. *Annals of Surgical Oncology*, **2011**, 18, 3285-91	3.1	18
130	Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. *Investigational New Drugs*, **2011**, 29, 1057-65	4.3	8
129	SEOM clinical guidelines for the treatment of pancreatic cancer. *Clinical and Translational Oncology*, **2011**, 13, 528-35	3.6	3
128	Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction. *Stem Cells*, **2011**, 29, 418-29	5.8	75

127	MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. *Clinical Cancer Research*, **2011**, 17, 2799-806	12.9	188
126	Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. *Clinical Cancer Research*, **2011**, 17, 5793-800	12.9	175
125	Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. *Journal of Clinical Oncology*, **2011**, 29, 4548-54	2.2	795
124	Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. *Cancer Biology and Therapy*, **2011**, 12, 598-609	4.6	92
123	A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. *Molecular Cancer Therapeutics*, **2011**, 10, 1311-6	6.1	307
122	Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. *Molecular Cancer Therapeutics*, **2011**, 10, 3-8	6.1	208
121	SMURF1 amplification promotes invasiveness in pancreatic cancer. *PLoS ONE*, **2011**, 6, e23924	3.7	39
120	Targeted Therapeutics in Cancer Treatment **2011**, 403-461		
119	Quantifying the relative amount of mouse and human DNA in cancer xenografts using species-specific variation in gene length. *BioTechniques*, **2010**, 48, 211-8	2.5	27
118	Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. *Journal of the National Cancer Institute*, **2010**, 102, 340-51	9.7	340
117	A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. *Molecular Cancer Therapeutics*, **2010**, 9, 311-8	6.1	34
116	A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. *Molecular Cancer Therapeutics*, **2010**, 9, 2582-92	6.1	78
115	A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. *Translational Oncology*, **2010**, 3, 373-9	4.9	16
114	Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. *Clinical Colorectal Cancer*, **2010**, 9, 297-304	3.8	17
113	Tumor-initiating cells are rare in many human tumors. *Cell Stem Cell*, **2010**, 7, 279-82	18	182
112	A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. *Journal of Molecular Diagnostics*, **2010**, 12, 292-9	5.1	86
111	Pancreatic cancer. *New England Journal of Medicine*, **2010**, 362, 1605-17	59.2	2151
110	Approach to early-onset colorectal cancer: clinicopathological, familial, molecular and immunohistochemical characteristics. *World Journal of Gastroenterology*, **2010**, 16, 3697-703	5.6	34

109	Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. *Investigational New Drugs*, **2010**, 28, 334-42	4.3	38
108	DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. *Journal of Clinical Oncology*, **2009**, 27, 1806-13	2.2	793
107	Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. *Clinical Cancer Research*, **2009**, 15, 6519-28	12.9	72
106	Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. *Molecular Cancer Therapeutics*, **2009**, 8, 1484-93	6.1	37
105	[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. *Journal of Clinical Oncology*, **2009**, 27, 2697-704	2.2	108
104	Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies. *Clinical Cancer Research*, **2009**, 15, 3591-9	12.9	27
103	A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. *Cancer Biology and Therapy*, **2009**, 8, 2013-24	4.6	96
102	The hedgehog pathway and pancreatic cancer. *New England Journal of Medicine*, **2009**, 361, 2094-6	59.2	94
101	Fenugreek: a naturally occurring edible spice as an anticancer agent. *Cancer Biology and Therapy*, **2009**, 8, 272-8	4.6	60
100	A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. *Molecular Cancer Therapeutics*, **2009**, 8, 310-4	6.1	219
99	Consensus on the treatment of pancreatic cancer in Spain. *Clinical and Translational Oncology*, **2009**, 11, 290-301	3.6	4
98	Characterizing DNA methylation patterns in pancreatic cancer genome. *Molecular Oncology*, **2009**, 3, 425-38	7.9	115
97	Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. *Gastroenterology*, **2009**, 137, 1102-13	13.3	272
96	Isolated recurrence of distal adenocarcinoma of the extrahepatic bile duct on a draining sinus scar after curative resection: case report and review of the literature. *World Journal of Surgical Oncology*, **2009**, 7, 96	3.4	1
95	Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. *Clinical Cancer Research*, **2009**, 15, 4138-46	12.9	76
94	Mycophenolate mofetil: An update. *Drugs of Today*, **2009**, 45, 521-32	2.5	56
93	Methylation alterations are not a major cause of PTTG1 misregulation. *BMC Cancer*, **2008**, 8, 110	4.8	4
92	Novel microtubule-interacting phenoxy pyridine and phenyl sulfanyl pyridine analogues for cancer therapy. *Journal of Medicinal Chemistry*, **2008**, 51, 5953-7	8.3	23

91	Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science*, **2008**, 321, 1801-6	33.3	3223
90	New scaffolds for the design of selective estrogen receptor modulators. *Organic and Biomolecular Chemistry*, **2008**, 6, 3486-96	3.9	24
89	Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. *Journal of Proteome Research*, **2008**, 7, 4651-8	5.6	37
88	Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. *Journal of Clinical Oncology*, **2008**, 26, 5504-10	2.2	94
87	Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. *Cancer Research*, **2008**, 68, 2841-9	10.1	84
86	Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. *Molecular Cancer Therapeutics*, **2008**, 7, 3275-84	6.1	70
85	Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. *Cancer Biology and Therapy*, **2008**, 7, 1146-56	4.6	151
84	A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. *Clinical Cancer Research*, **2008**, 14, 5602-9	12.9	26
83	Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. *Journal of Clinical Oncology*, **2008**, 26, 4172-9	2.2	58
82	Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. *Journal of Clinical Oncology*, **2008**, 26, 3503-10	2.2	290
81	Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. *Cancer Chemotherapy and Pharmacology*, **2008**, 61, 423-33	3.5	32
80	Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. *Cancer Chemotherapy and Pharmacology*, **2008**, 63, 181-8	3.5	29
79	Determination of salirasib (S-trans,trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2008**, 869, 142-5	3.2	3
78	Clinical development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: what lessons have we learned?. *Advances in Experimental Medicine and Biology*, **2008**, 610, 128-43	3.6	4
77	Targeted Therapeutics in Cancer Treatment **2007**, 117-148		
76	A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2007**, 846, 1-7	3.2	43
75	Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2007**, 856, 198-204	3.2	10
74	Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors. *Pediatric Blood and Cancer*, **2007**, 49, 352-7	3	12

73	Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays. *Molecular Cancer Therapeutics*, **2007**, 6, 515-23	6.1	22
72	Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. *Cancer Biology and Therapy*, **2007**, 6, 432-8	4.6	159
71	Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. *Clinical Cancer Research*, **2007**, 13, 3731-7	12.9	237
70	Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer. *Molecular Cancer Therapeutics*, **2007**, 6, 1509-16	6.1	16
69	Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?. *Clinical Cancer Research*, **2007**, 13, 4664-6	12.9	40
68	Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. *Molecular Cancer Therapeutics*, **2007**, 6, 1079-88	6.1	28
67	A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). *Journal of Thoracic Oncology*, **2007**, 2, 1036-41	8.9	130
66	Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. *Journal of Clinical Oncology*, **2007**, 25, 3230-7	2.2	988
65	Exploiting novel molecular targets in gastrointestinal cancers. *World Journal of Gastroenterology*, **2007**, 13, 5845-56	5.6	16
64	Epidermal Growth Factor Receptor Inhibition in Non‐Small Cell Lung Cancer. *Translational Medicine Series*, **2007**, 81-96		
63	Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2006**, 1766, 217-29	11.2	27
62	C-fos assessment as a marker of anti-epidermal growth factor receptor effect. *Cancer Research*, **2006**, 66, 2385-90	10.1	28
61	Cetuximab in squamous cell carcinoma of the head and neck. *Future Oncology*, **2006**, 2, 449-57	3.6	3
60	An in vivo platform for translational drug development in pancreatic cancer. *Clinical Cancer Research*, **2006**, 12, 4652-61	12.9	364
59	A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. *Clinical Cancer Research*, **2006**, 12, 4274-82	12.9	28
58	Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. *Clinical Cancer Research*, **2006**, 12, 7406-13	12.9	17
57	CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. *Journal of the National Cancer Institute*, **2006**, 98, 1714-23	9.7	93
56	Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. *Journal of Clinical Oncology*, **2006**, 24, 2252-60	2.2	122

55	Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration. *Molecular Cancer Therapeutics*, **2006**, 5, 1895-903	6.1	12
54	A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. *Clinical Cancer Research*, **2006**, 12, 5755-63	12.9	191
53	Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. *Journal of the National Cancer Institute*, **2006**, 98, 1739-42	9.7	218
52	Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. *Clinical Cancer Research*, **2006**, 12, 2492-7	12.9	127
51	Assessment of celecoxib pharmacodynamics in pancreatic cancer. *Molecular Cancer Therapeutics*, **2006**, 5, 3240-7	6.1	29
50	Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. *Molecular Cancer Therapeutics*, **2006**, 5, 787-96	6.1	77
49	Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue. *Clinical Cancer Research*, **2006**, 12, 2158-65	12.9	11
48	Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. *Clinical Cancer Research*, **2006**, 12, 6517-22	12.9	80
47	Benzoylphenylurea sulfur analogues with potent antitumor activity. *Journal of Medicinal Chemistry*, **2006**, 49, 2357-60	8.3	37
46	Multitargeted therapy: can promiscuity be praised in an era of political correctness?. *Critical Reviews in Oncology/Hematology*, **2006**, 59, 150-8	7	24
45	Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. *Investigational New Drugs*, **2006**, 24, 291-7	4.3	60
44	Intracellular signal transduction pathway proteins as targets for cancer therapy. *Journal of Clinical Oncology*, **2005**, 23, 5386-403	2.2	155
43	Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. *Cancer Research*, **2005**, 65, 3003-10	10.1	98
42	Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2005**, 819, 73-80	3.2	52
41	Design, synthesis and biological evaluation of novel riccardiphenol analogs. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 2873-80	3.4	16
40	Current status of mammalian target of rapamycin inhibitors in lung cancer. *Clinical Lung Cancer*, **2005**, 7 Suppl 1, S13-8	4.9	12
39	Blockade of epidermal growth factor receptor (EGFR) activity. *Critical Reviews in Oncology/Hematology*, **2005**, 53, 179-92	7	17
38	In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent. *Clinical Cancer Research*, **2005**, 11, 8503-11	12.9	9

37	Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity. *Expert Review of Anticancer Therapy*, **2005**, 5, 727-35	3.5	2
36	Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. *Cancer Biology and Therapy*, **2005**, 4, 1381-6	4.6	33
35	Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. *Cancer Biology and Therapy*, **2005**, 4, 548-54	4.6	114
34	Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. *Journal of Clinical Oncology*, **2005**, 23, 5294-304	2.2	608
33	Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers. *Molecular Cancer Therapeutics*, **2005**, 4, 1860-6	6.1	30
32	Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. *Journal of Clinical Oncology*, **2004**, 22, 909-18	2.2	847
31	New target, new drug, old paradigm. *Journal of Clinical Oncology*, **2004**, 22, 2270-2	2.2	17
30	Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. *Clinical Cancer Research*, **2004**, 10, 6522-7	12.9	71
29	A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. *Clinical Cancer Research*, **2004**, 10, 6512-21	12.9	53
28	The V599E BRAF mutation is uncommon in biliary tract cancers. *Modern Pathology*, **2004**, 17, 1386-91	9.8	38
27	Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors. *Clinical Lung Cancer*, **2004**, 6 Suppl 1, S30-4	4.9	15
26	Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. *Cancer*, **2004**, 101, 1609-15	6.4	83
25	Synthesis and antitumor evaluation of benzoylphenylurea analogs. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 2213-6	2.9	22
24	Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. *Journal of Clinical Oncology*, **2004**, 22, 77-85	2.2	677
23	An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. *Cancer Research*, **2004**, 64, 9139-43	10.1	224
22	Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer. *Clinical Colorectal Cancer*, **2004**, 4, 51-62	3.8	13
21	Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. *Clinical Cancer Research*, **2004**, 10, 8059-67	12.9	329
20	New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. *Breast Cancer Research*, **2004**, 6, 219-24	8.3	71

19	Recent advances in the pharmacological treatment of colorectal cancer. *Expert Opinion on Investigational Drugs*, **2003**, 12, 423-34	5.9	7
18	Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of Erlotinib (Tarceva). *Seminars in Oncology*, **2003**, 30, 25-33	5.5	67
17	Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2003**, 793, 413-20	3.2	55
16	Identification of novel cellular targets in biliary tract cancers using global gene expression technology. *American Journal of Pathology*, **2003**, 163, 217-29	5.8	106
15	Developing inhibitors of the epidermal growth factor receptor for cancer treatment. *Journal of the National Cancer Institute*, **2003**, 95, 851-67	9.7	306
14	Development of the epidermal growth factor receptor inhibitor OSI-774. *Seminars in Oncology*, **2003**, 30, 23-31	5.5	127
13	Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774). *Advances in Experimental Medicine and Biology*, **2003**, 532, 235-46	3.6	45
12	Promising developments in targeted therapies for non-small-cell lung cancer. *Clinical Lung Cancer*, **2002**, 4, 111-23	4.9	2
11	Angiogenesis inhibitors in clinical development for lung cancer. *Seminars in Oncology*, **2002**, 29, 66-77	5.5	43
10	The epidermal growth factor receptor: a new target for anticancer therapy. *Current Problems in Cancer*, **2002**, 26, 109-64	2.3	50
9	Pancreatic cancer. *Current Problems in Cancer*, **2002**, 26, 176-275	2.3	221
8	An introduction to pancreatic adenocarcinoma genetics, pathology and therapy. *Cancer Biology and Therapy*, **2002**, 1, 607-13	4.6	40
7	Development of matrix metalloproteinase inhibitors in cancer therapy. *Hematology/Oncology Clinics of North America*, **2002**, 16, 1189-227	3.1	20
6	Development of matrix metalloproteinase inhibitors in cancer therapy. *Journal of the National Cancer Institute*, **2001**, 93, 178-93	9.7	666
5	Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. *Journal of Clinical Oncology*, **2001**, 19, 2493-503	2.2	34
4	Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. *Journal of Clinical Oncology*, **2001**, 19, 3267-79	2.2	885
3	Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. *Journal of Clinical Oncology*, **2001**, 19, 2937-47	2.2	38
2	The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. *Oncogene*, **2000**, 19, 6680-6	9.2	520

1	Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. *Journal of Clinical Oncology*, **2000**, 18, 178-86	2.2	72